论文部分内容阅读
目的探讨丹红注射液联合辛伐他汀治疗老年冠状动脉粥样硬化性心脏病(简称冠心病)合并高脂血症患者的临床疗效。方法将入选的105例冠心病合并高脂血症老年患者随机分为治疗组(54例)和对照组(51例),两组患者均给予冠心病对症治疗和辛伐他汀调脂治疗,治疗组加用丹红注射液,1个月后对比冠心病疗效与血脂水平。结果治疗1个月后,治疗组与对照组总胆固醇分别为(5.17±0.95)mmol/L和(5.65±0.90)mmol/L,甘油三酯分别为(1.84±0.45)mmol/L和(2.07±0.49)mmol/L,低密度脂蛋白胆固醇分别为(2.39±0.54)mmol/L和(2.59±0.48)mmol/L,差异均有统计学意义(P<0.05)。治疗组左室收缩末径为(43.4±4.6)mm,低于对照组的(45.5±4.9)mm;左室射血分数为(49.1±6.3)%,高于对照组的(46.6±5.7)%,差异均有统计学意义(P<0.05);治疗组冠心病治疗显效率为61.11%,总有效率为96.30%,均高于对照组的41.18%和86.27%(χ2=4.173,P=0.041)。治疗组与对照组的不良反应发生率分别为11.11%和13.73%,差异无统计学意义(χ2=0.165,P=0.684)。结论辛伐他汀调脂联合丹红注射液治疗老年冠心病合并高脂血症患者能进一步调节血脂水平,提高心脏射血功能,减少心绞痛发作,具有较高的临床安全性。
Objective To investigate the clinical effects of Danhong injection combined with simvastatin in the treatment of elderly patients with coronary atherosclerotic heart disease (referred to as coronary heart disease) and hyperlipidemia. Methods A total of 105 elderly patients with coronary heart disease and hyperlipidemia were randomly divided into treatment group (54 cases) and control group (51 cases). Both groups were given symptomatic treatment of coronary heart disease and simvastatin lipid-lowering treatment Group with Danhong injection, 1 month after the comparison of coronary heart disease efficacy and blood lipid levels. Results After 1 month of treatment, total cholesterol (5.17 ± 0.95) mmol / L and (5.65 ± 0.90) mmol / L and (1.84 ± 0.45) mmol / L and ± 0.49 mmol / L and LDL cholesterol were (2.39 ± 0.54) mmol / L and (2.59 ± 0.48) mmol / L, respectively, with statistical significance (P <0.05). The mean systolic diameter of the left ventricle in the treatment group was (43.4 ± 4.6) mm, lower than that in the control group (45.5 ± 4.9) mm; the left ventricular ejection fraction was (49.1 ± 6.3)% in the treatment group and (46.6 ± 5.7) %, Respectively. The difference was statistically significant (P <0.05). The effective rate of treatment for CHD was 61.11% and the total effective rate was 96.30%, which were higher than 41.18% and 86.27% of the control group (χ2 = 4.173, P = 0.041). Adverse reactions in treatment group and control group were 11.11% and 13.73% respectively, with no significant difference (χ2 = 0.165, P = 0.684). Conclusion Simvastatin combined with Danhong injection in elderly patients with coronary heart disease and hyperlipidemia can further regulate blood lipid levels, improve cardiac ejection function, reduce angina pectoris, and have high clinical safety.